Prognosis stratification of cancer patients treated with immune checkpoint inhibitors through lung immune prognostic index: a meta-analysis and systematic review

Although numerous studies have reported the prognostic value of the lung immune prognostic index (LIPI) in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs), the prognostic value of the LIPI in a pancancer setting remains unclear. A comprehensive search was...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2024-04, Vol.24 (1), p.523-523, Article 523
Main Authors: Guo, Yusheng, Pan, Yao, Wan, Jiayu, Gong, Bingxin, Li, Yi, Kan, Xuefeng, Zheng, Chuansheng
Format: Article
Language:English
Subjects:
Biomarkers
Cancer
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - immunology
Carcinoma, Non-Small-Cell Lung - mortality
Carcinoma, Non-Small-Cell Lung - pathology
Clinical outcomes
Disease control
Drug therapy
Humans
Immune checkpoint inhibitors
Immune Checkpoint Inhibitors - therapeutic use
Immunotherapy
Liver cancer
Lung cancer
Lung immune prognostic index
Lung Neoplasms - drug therapy
Lung Neoplasms - immunology
Lung Neoplasms - mortality
Lung Neoplasms - pathology
Medical prognosis
Meta-analysis
Non-small cell lung carcinoma
Patient outcomes
Patients
Prognosis
Prognosis stratification
Progression-Free Survival
Small cell lung carcinoma
Solid tumors
Systematic review
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although numerous studies have reported the prognostic value of the lung immune prognostic index (LIPI) in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs), the prognostic value of the LIPI in a pancancer setting remains unclear. A comprehensive search was conducted until July 2023 across the PubMed, Embase, Web of Science, and Cochrane Library databases to identify relevant studies evaluating the prognostic value of the LIPI in cancer patients treated with ICIs. The outcomes were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). We described and compared the pooled outcomes by stratifying the patients based on different groupings of LIPI (good vs. intermediate [0 vs. 1], good vs. poor [0 vs. 2], and good vs. intermediate / poor [0 vs. 1 + 2]). A total of 9959 patients in 35 studies were included. A higher score of LIPI was associated with impaired OS. The pooled HRs were 1.69 (95% CI: 1.55-1.85, p 
ISSN:1471-2407
1471-2407
DOI:10.1186/s12885-024-12271-0